title: Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
authors.affiliation: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
authors.forename: Edna M Juarez
authors.initials: EM
authors.lastname: Ramirez Tello
authors.affiliation: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas. Electronic address: menfil@gmail.com.
authors.forename: Menfil A
authors.initials: MA
authors.lastname: Orellana-Barrios
authors.affiliation: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Nugent
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D000068896:Canagliflozin / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007328:Insulin / Q000378:metabolism; D007668:Kidney / Q000187:drug effects; D008297:Male; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin